Results 21 to 30 of about 188,223 (344)
Best Practice & Research Clinical Haematology, 2011 Rituximab has become a ubiquitous component of treatment regimens for follicular non-Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells resist rituximab-mediated destruction remain unclear. Rituximab relies in part on immune effector mechanisms for its antitumor effect, and thus resistance may be mediated not only by
Andrew R, Rezvani, David G, Maloney
openaire +2 more sources
Rituximab, MS, and pregnancy [PDF]
Neurology Neuroimmunology & Neuroinflammation, 2020 To describe the safety and efficacy of rituximab (RTX) in MS and pregnancy, we conducted a retrospective cohort study of 74 pregnancies among 55 women treated with RTX for MS and their offspring.We used prospectively collected information from the electronic health record at Kaiser Permanente Southern California between 2012 and 2019 of mother and baby
Jessica B. Smith +5 more
openaire +2 more sources
Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy
American Journal of Ophthalmology Case Reports, 2016 Purpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and
Gunay Uludag +6 more
doaj +1 more source
Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. [PDF]
, 2017 We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome.
Mauro, Francesca Romana
core +1 more source
American Journal of Neuroradiology, 2010 Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
David T, Selewski +4 more
openaire +2 more sources
RITUXIMAB-INDUCED SEVERE ACUTE THROMBOCYTOPENIA IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA
Hematology, Transfusion and Cell Therapy, 2022 Objective: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological.
Taha Ulutan Kars +3 more
doaj
Haematologica, 2013 Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high ...
Clifton C. Mo +9 more
doaj +1 more source
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing [PDF]
The Korean Journal of Internal Medicine, 2023 Background/Aims Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.
Min Ji Jeon +3 more
doaj +1 more source
Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production [PDF]
, 2017 Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), based on the recognition of IgG-opsonized targets by the low-affinity receptor for IgG FcγRIIIA/CD16, represents one of the main mechanisms by which therapeutic antibodies
Battella, Simone +9 more
core +6 more sources
Journal of Hematology & Oncology, 2012 Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab.
Zinzani Pier +14 more
doaj +1 more source